Search

Your search keyword '"Davis, R. Eric"' showing total 497 results
Start Over Author "Davis, R. Eric"
497 results on '"Davis, R. Eric"'

3. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Author

Cherng, Hua-Jay J., Alig, Stefan K., Oki, Yasuhiro, Nastoupil, Loretta J., Fayad, Luis, Neelapu, Sattva S., Turturro, Francesco, Hagemeister, Fredrick, Craig, Alexander F. M., Macaulay, Charles W., Rodriguez, Maria Alma, Lee, Hun Ju, McDonnell, Timothy J., Flowers, Christopher R., Vega, Francisco, Green, Michael R., Feng, Lei, Kurtz, David M., Alizadeh, Ash A., Davis, R. Eric, and Westin, Jason R.

Published
2023
Full Text
View/download PDF

7. Impact of PIK3CAgain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies

Author

Bettazova, Nardjas, Senavova, Jana, Kupcova, Kristyna, Sovilj, Dana, Rajmonova, Anezka, Andera, Ladislav, Svobodova, Karla, Berkova, Adela, Zemanova, Zuzana, Daumova, Lenka, Herman, Vaclav, Dolníkova, Alexandra, Davis, R. Eric, Trneny, Marek, Klener, Pavel, and Havranek, Ondrej

Abstract

•PIK3CAgain and PTENloss decrease the dependence of MCL cells on BCR signaling and antiapoptotic BCL2.•PIK3CAgain and PTENloss lead to complex metabolic rewiring and increased survival of MCL cells under hypoxia.

Published
2024
Full Text
View/download PDF

8. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

Author

Gordon, Max J., primary, Feng, Lei, additional, Strati, Paolo, additional, Lee, Hun Ju, additional, Hagemeister, Fredrick B., additional, Westin, Jason R., additional, Samaniego, Felipe, additional, Marques‐Piubelli, Mario L., additional, Vega Vazquez, Francisco, additional, Parra Cuentas, Edwin R., additional, Solis‐Soto, Luisa M., additional, Ma, Wencai, additional, Wang, Jing, additional, Claret, Linda, additional, Averill, Barbara, additional, Ibanez, Karina, additional, Fayad, Luis E., additional, Flowers, Christopher R., additional, Green, Michael R., additional, Davis, R. Eric, additional, Neelapu, Sattva S., additional, Fowler, Nathan H., additional, and Nastoupil, Loretta J., additional

Published
2023
Full Text
View/download PDF

10. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

Author

Gordon, Max J., Feng, Lei, Strati, Paolo, Lee, Hun Ju, Hagemeister, Fredrick B., Westin, Jason R., Samaniego, Felipe, Marques‐Piubelli, Mario L., Vega Vazquez, Francisco, Parra Cuentas, Edwin R., Solis‐Soto, Luisa M., Ma, Wencai, Wang, Jing, Claret, Linda, Averill, Barbara, Ibanez, Karina, Fayad, Luis E., Flowers, Christopher R., Green, Michael R., and Davis, R. Eric

Subjects
MUCOSA-associated lymphoid tissue lymphoma, LENALIDOMIDE, BRUTON tyrosine kinase, RITUXIMAB, FOLLICULAR lymphoma
Abstract

Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non‐Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because standard treatments are not curative, patients often receive multiple lines of therapy with associated toxicity—rationally designed, combination therapies with curative potential are needed. The immunomodulatory drug lenalidomide was evaluated in combination with rituximab for the frontline treatment of FL in the phase 3 RELEVANCE study. Ibrutinib, an oral Bruton tyrosine kinase inhibitor, is active in NHL and was evaluated in combination with lenalidomide, rituximab, and ibrutinib (IRR) in a phase 1 study. Methods: The authors conducted an open‐label, phase 2 clinical trial of IRR for previously untreated FL and MZL. The primary end point was progression‐free survival (PFS) at 24 months. Results: This study included 48 participants with previously untreated FL grade 1–3a (N = 38), or MZL (N = 10). Participants received 12, 28‐day cycles of lenalidomide (15 mg, days 1–21 cycle 1; 20 mg, cycles 2–12), rituximab (375 mg/m2 weekly in cycle 1; day 1 cycles 2‐12), and ibrutinib 560 mg daily. With a median follow‐up of 65.3 months, the estimated PFS at 24 months was 78.8% (95% confidence interval [CI], 68.0%–91.4%) and 60‐month PFS was 59.7% (95% CI, 46.6%–76.4%). One death occurred unrelated to disease progression. Grade 3–4 adverse events were observed in 64.6%, including 50% with grade 3–4 rash. Conclusions: IRR is highly active as frontline therapy for FL and MZL. Compared to historical results with lenalidomide and rituximab, PFS is similar with higher grade 3–4 toxicity, particularly rash. The study was registered with ClinicalTrials.gov (NCT02532257). After 5 years of follow‐up from a phase 2 clinical trial of ibrutinib, lenalidomide, and rituximab in previously untreated patients with follicular and marginal zone lymphoma, the 5‐year progression‐free survival rate was 59.7% and the overall survival rate was 97.9%. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

Author

Cascone, Tina, McKenzie, Jodi A., Mbofung, Rina M., Punt, Simone, Wang, Zhe, Xu, Chunyu, Williams, Leila J., Wang, Zhiqiang, Bristow, Christopher A., Carugo, Alessandro, Peoples, Michael D., Li, Lerong, Karpinets, Tatiana, Huang, Lu, Malu, Shruti, Creasy, Caitlin, Leahey, Sara E., Chen, Jiong, Chen, Yuan, Pelicano, Helen, Bernatchez, Chantale, Gopal, Y.N. Vashisht, Heffernan, Timothy P., Hu, Jianhua, Wang, Jing, Amaria, Rodabe N., Garraway, Levi A., Huang, Peng, Yang, Peiying, Wistuba, Ignacio I., Woodman, Scott E., Roszik, Jason, Davis, R. Eric, Davies, Michael A., Heymach, John V., Hwu, Patrick, and Peng, Weiyi

Published
2018
Full Text
View/download PDF

12. BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment

Author

Piya, Sujan, Mu, Hong, Bhattacharya, Seemana, Lorenzi, Philip L., Davis, R. Eric, McQueen, Teresa, Ruvolo, Vivian, Baran, Natalia, Wang, Zhiqiang, Qian, Yimin, Crews, Craig M., Konopleva, Marina, Ishizawa, Jo, You, M. James, Kantarjian, Hagop, Andreeff, Michael, and Borthakur, Gautam

Subjects
Stem cells -- Research, Gene expression -- Research, Transcription factors -- Research, Acute myelocytic leukemia -- Genetic aspects -- Research, Cysteine, Genes, Criminal investigation, Oxidative stress, Proteins, Proteomics, Cystine, Myeloid leukemia, Health care industry
Abstract

The antileukemic effect of inhibiting bromodomain and extra-terminal domain-containing (BET-containing) proteins (BETPs) such as BRD4 has largely been largely attributed to transcriptional downregulation of cellular anabolic and antiapoptotic processes, but its effect on the bone marrow microenvironment, a sanctuary favoring the persistence of leukemic stem/progenitor cells, is unexplored. Sustained degradation of BETP with the small-molecule BET proteolysistargeting chimera (PROTAC) ARV-825 resulted in a marked downregulation of surface CXCR4 and CD44, key proteins in leukemia-microenvironment interactions, in acute myeloid leukemia (AML) cells. Abrogation of surface CXCR4 expression impaired SDF-1[alpha]-directed migration and was mediated through transcriptional downregulation of PIM1 kinase, which in turn phosphorylates CXCR4 and facilitates its surface localization. Downregulation of CD44, including isoforms CD44v8- 10 impaired cystine uptake, lowered intracellular reduced glutathione, and increased oxidative stress. More important, BETP degradation markedly decreased the [CD34.sup.+][CD38.sup.-][CD90.sup.-][CD45RA.sup.+] leukemic stem cell population and, alone or in combination with cytarabine, prolonged survival in a mouse model of human leukemia that included AML patient-derived xenografts (AML-PDX). Gene expression profiling and single-cell proteomics confirmed a downregulation of the gene signatures associated with 'sternness' in AML and Wnt/[beta]-catenin and Myc pathways. Hence, BETP degradation by ARV-825 simultaneously targets cell-intrinsic signaling, stromal interactions, and metabolism in AML., Introduction Acute myeloid leukemia (AML) is the most common hematological malignancy in adults and the second most common one in children (1). Aberrant epigenetic events associated with DNA/chromatin modification that [...]

Published
2019
Full Text
View/download PDF

13. Supplementary Tables 1-9 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

Author

Bhattacharya, Seemana, primary, Piya, Sujan, primary, Ma, Huaxian, primary, Sharma, Priyanka, primary, Zhang, Qi, primary, Baran, Natalia, primary, Ruvolo, Vivian R., primary, McQueen, Teresa, primary, Davis, R. Eric, primary, Pourebrahim, Rasoul, primary, Konopleva, Marina, primary, Kantarjian, Hagop, primary, Cosford, Nicholas D. P., primary, Andreeff, Michael, primary, and Borthakur, Gautam, primary

Published
2023
Full Text
View/download PDF

15. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma

Author

Zhang, Xiaohui, Lee, Hans C., Shirazi, Fazal, Baladandayuthapani, Veerabhadran, Lin, Heather, Kuiatse, Isere, Wang, Hua, Jones, Richard J., Berkova, Zuzana, Singh, Ram Kumar, Lu, Jing, Qian, Yimin, Raina, Kanak, Coleman, Kevin G., Crews, Craig M., Li, Bingzong, Wang, Huihan, Hailemichael, Yared, Thomas, Sheeba K., Wang, Zhiqiang, Davis, R. Eric, and Orlowski, Robert Z.

Published
2018
Full Text
View/download PDF

16. Data from Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

Author

Jaiswal, Ashvin R., primary, Liu, Arthur J., primary, Pudakalakatti, Shivanand, primary, Dutta, Prasanta, primary, Jayaprakash, Priyamvada, primary, Bartkowiak, Todd, primary, Ager, Casey R., primary, Wang, Zhi-Qiang, primary, Reuben, Alexandre, primary, Cooper, Zachary A., primary, Ivan, Cristina, primary, Ju, Zhenlin, primary, Nwajei, Felix, primary, Wang, Jing, primary, Davies, Michael A., primary, Davis, R. Eric, primary, Wargo, Jennifer A., primary, Bhattacharya, Pratip K., primary, Hong, David S., primary, and Curran, Michael A., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figures from Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

Author

Jaiswal, Ashvin R., primary, Liu, Arthur J., primary, Pudakalakatti, Shivanand, primary, Dutta, Prasanta, primary, Jayaprakash, Priyamvada, primary, Bartkowiak, Todd, primary, Ager, Casey R., primary, Wang, Zhi-Qiang, primary, Reuben, Alexandre, primary, Cooper, Zachary A., primary, Ivan, Cristina, primary, Ju, Zhenlin, primary, Nwajei, Felix, primary, Wang, Jing, primary, Davies, Michael A., primary, Davis, R. Eric, primary, Wargo, Jennifer A., primary, Bhattacharya, Pratip K., primary, Hong, David S., primary, and Curran, Michael A., primary

Published
2023
Full Text
View/download PDF

18. Data from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

Author

Bhattacharya, Seemana, primary, Piya, Sujan, primary, Ma, Huaxian, primary, Sharma, Priyanka, primary, Zhang, Qi, primary, Baran, Natalia, primary, Ruvolo, Vivian R., primary, McQueen, Teresa, primary, Davis, R. Eric, primary, Pourebrahim, Rasoul, primary, Konopleva, Marina, primary, Kantarjian, Hagop, primary, Cosford, Nicholas D. P., primary, Andreeff, Michael, primary, and Borthakur, Gautam, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 1 from Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

Author

Jaiswal, Ashvin R., primary, Liu, Arthur J., primary, Pudakalakatti, Shivanand, primary, Dutta, Prasanta, primary, Jayaprakash, Priyamvada, primary, Bartkowiak, Todd, primary, Ager, Casey R., primary, Wang, Zhi-Qiang, primary, Reuben, Alexandre, primary, Cooper, Zachary A., primary, Ivan, Cristina, primary, Ju, Zhenlin, primary, Nwajei, Felix, primary, Wang, Jing, primary, Davies, Michael A., primary, Davis, R. Eric, primary, Wargo, Jennifer A., primary, Bhattacharya, Pratip K., primary, Hong, David S., primary, and Curran, Michael A., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

Author

Bhattacharya, Seemana, primary, Piya, Sujan, primary, Ma, Huaxian, primary, Sharma, Priyanka, primary, Zhang, Qi, primary, Baran, Natalia, primary, Ruvolo, Vivian R., primary, McQueen, Teresa, primary, Davis, R. Eric, primary, Pourebrahim, Rasoul, primary, Konopleva, Marina, primary, Kantarjian, Hagop, primary, Cosford, Nicholas D. P., primary, Andreeff, Michael, primary, and Borthakur, Gautam, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Author

Chen, Pei-Ling, primary, Roh, Whijae, primary, Reuben, Alexandre, primary, Cooper, Zachary A., primary, Spencer, Christine N., primary, Prieto, Peter A., primary, Miller, John P., primary, Bassett, Roland L., primary, Gopalakrishnan, Vancheswaran, primary, Wani, Khalida, primary, De Macedo, Mariana Petaccia, primary, Austin-Breneman, Jacob L., primary, Jiang, Hong, primary, Chang, Qing, primary, Reddy, Sangeetha M., primary, Chen, Wei-Shen, primary, Tetzlaff, Michael T., primary, Broaddus, Russell J., primary, Davies, Michael A., primary, Gershenwald, Jeffrey E., primary, Haydu, Lauren, primary, Lazar, Alexander J., primary, Patel, Sapna P., primary, Hwu, Patrick, primary, Hwu, Wen-Jen, primary, Diab, Adi, primary, Glitza, Isabella C., primary, Woodman, Scott E., primary, Vence, Luis M., primary, Wistuba, Ignacio I., primary, Amaria, Rodabe N., primary, Kwong, Lawrence N., primary, Prieto, Victor, primary, Davis, R. Eric, primary, Ma, Wencai, primary, Overwijk, Willem W., primary, Sharpe, Arlene H., primary, Hu, Jianhua, primary, Futreal, P. Andrew, primary, Blando, Jorge, primary, Sharma, Padmanee, primary, Allison, James P., primary, Chin, Lynda, primary, and Wargo, Jennifer A., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Tables 1 - 11 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Author

Chen, Pei-Ling, primary, Roh, Whijae, primary, Reuben, Alexandre, primary, Cooper, Zachary A., primary, Spencer, Christine N., primary, Prieto, Peter A., primary, Miller, John P., primary, Bassett, Roland L., primary, Gopalakrishnan, Vancheswaran, primary, Wani, Khalida, primary, De Macedo, Mariana Petaccia, primary, Austin-Breneman, Jacob L., primary, Jiang, Hong, primary, Chang, Qing, primary, Reddy, Sangeetha M., primary, Chen, Wei-Shen, primary, Tetzlaff, Michael T., primary, Broaddus, Russell J., primary, Davies, Michael A., primary, Gershenwald, Jeffrey E., primary, Haydu, Lauren, primary, Lazar, Alexander J., primary, Patel, Sapna P., primary, Hwu, Patrick, primary, Hwu, Wen-Jen, primary, Diab, Adi, primary, Glitza, Isabella C., primary, Woodman, Scott E., primary, Vence, Luis M., primary, Wistuba, Ignacio I., primary, Amaria, Rodabe N., primary, Kwong, Lawrence N., primary, Prieto, Victor, primary, Davis, R. Eric, primary, Ma, Wencai, primary, Overwijk, Willem W., primary, Sharpe, Arlene H., primary, Hu, Jianhua, primary, Futreal, P. Andrew, primary, Blando, Jorge, primary, Sharma, Padmanee, primary, Allison, James P., primary, Chin, Lynda, primary, and Wargo, Jennifer A., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figures 1 - 13 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Author

Chen, Pei-Ling, primary, Roh, Whijae, primary, Reuben, Alexandre, primary, Cooper, Zachary A., primary, Spencer, Christine N., primary, Prieto, Peter A., primary, Miller, John P., primary, Bassett, Roland L., primary, Gopalakrishnan, Vancheswaran, primary, Wani, Khalida, primary, De Macedo, Mariana Petaccia, primary, Austin-Breneman, Jacob L., primary, Jiang, Hong, primary, Chang, Qing, primary, Reddy, Sangeetha M., primary, Chen, Wei-Shen, primary, Tetzlaff, Michael T., primary, Broaddus, Russell J., primary, Davies, Michael A., primary, Gershenwald, Jeffrey E., primary, Haydu, Lauren, primary, Lazar, Alexander J., primary, Patel, Sapna P., primary, Hwu, Patrick, primary, Hwu, Wen-Jen, primary, Diab, Adi, primary, Glitza, Isabella C., primary, Woodman, Scott E., primary, Vence, Luis M., primary, Wistuba, Ignacio I., primary, Amaria, Rodabe N., primary, Kwong, Lawrence N., primary, Prieto, Victor, primary, Davis, R. Eric, primary, Ma, Wencai, primary, Overwijk, Willem W., primary, Sharpe, Arlene H., primary, Hu, Jianhua, primary, Futreal, P. Andrew, primary, Blando, Jorge, primary, Sharma, Padmanee, primary, Allison, James P., primary, Chin, Lynda, primary, and Wargo, Jennifer A., primary

Published
2023
Full Text
View/download PDF

27. Data from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Author

Chen, Pei-Ling, primary, Roh, Whijae, primary, Reuben, Alexandre, primary, Cooper, Zachary A., primary, Spencer, Christine N., primary, Prieto, Peter A., primary, Miller, John P., primary, Bassett, Roland L., primary, Gopalakrishnan, Vancheswaran, primary, Wani, Khalida, primary, De Macedo, Mariana Petaccia, primary, Austin-Breneman, Jacob L., primary, Jiang, Hong, primary, Chang, Qing, primary, Reddy, Sangeetha M., primary, Chen, Wei-Shen, primary, Tetzlaff, Michael T., primary, Broaddus, Russell J., primary, Davies, Michael A., primary, Gershenwald, Jeffrey E., primary, Haydu, Lauren, primary, Lazar, Alexander J., primary, Patel, Sapna P., primary, Hwu, Patrick, primary, Hwu, Wen-Jen, primary, Diab, Adi, primary, Glitza, Isabella C., primary, Woodman, Scott E., primary, Vence, Luis M., primary, Wistuba, Ignacio I., primary, Amaria, Rodabe N., primary, Kwong, Lawrence N., primary, Prieto, Victor, primary, Davis, R. Eric, primary, Ma, Wencai, primary, Overwijk, Willem W., primary, Sharpe, Arlene H., primary, Hu, Jianhua, primary, Futreal, P. Andrew, primary, Blando, Jorge, primary, Sharma, Padmanee, primary, Allison, James P., primary, Chin, Lynda, primary, and Wargo, Jennifer A., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figures from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

Author

Ni, Haiwen, primary, Shirazi, Fazal, primary, Baladandayuthapani, Veerabhadran, primary, Lin, Heather, primary, Kuiatse, Isere, primary, Wang, Hua, primary, Jones, Richard J., primary, Berkova, Zuzana, primary, Hitoshi, Yasumichi, primary, Ansell, Stephen M., primary, Treon, Steven P., primary, Thomas, Sheeba K., primary, Lee, Hans C., primary, Wang, Zhiqiang, primary, Davis, R. Eric, primary, and Orlowski, Robert Z., primary

Published
2023
Full Text
View/download PDF

29. Supplemental Methods and Tables from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models

Author

Benito, Juliana, primary, Ramirez, Marc S., primary, Millward, Niki Zacharias, primary, Velez, Juliana, primary, Harutyunyan, Karine G., primary, Lu, Hongbo, primary, Shi, Yue-xi, primary, Matre, Polina, primary, Jacamo, Rodrigo, primary, Ma, Helen, primary, Konoplev, Sergej, primary, McQueen, Teresa, primary, Volgin, Andrei, primary, Protopopova, Marina, primary, Mu, Hong, primary, Lee, Jaehyuk, primary, Bhattacharya, Pratip K., primary, Marszalek, Joseph R., primary, Davis, R. Eric, primary, Bankson, James A., primary, Cortes, Jorge E., primary, Hart, Charles P., primary, Andreeff, Michael, primary, and Konopleva, Marina, primary

Published
2023
Full Text
View/download PDF

30. Supplemental Figures 1-6 from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models

Author

Benito, Juliana, primary, Ramirez, Marc S., primary, Millward, Niki Zacharias, primary, Velez, Juliana, primary, Harutyunyan, Karine G., primary, Lu, Hongbo, primary, Shi, Yue-xi, primary, Matre, Polina, primary, Jacamo, Rodrigo, primary, Ma, Helen, primary, Konoplev, Sergej, primary, McQueen, Teresa, primary, Volgin, Andrei, primary, Protopopova, Marina, primary, Mu, Hong, primary, Lee, Jaehyuk, primary, Bhattacharya, Pratip K., primary, Marszalek, Joseph R., primary, Davis, R. Eric, primary, Bankson, James A., primary, Cortes, Jorge E., primary, Hart, Charles P., primary, Andreeff, Michael, primary, and Konopleva, Marina, primary

Published
2023
Full Text
View/download PDF

31. Supplemental File 3 from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition

Author

Ishizawa, Jo, primary, Nakamaru, Kenji, primary, Seki, Takahiko, primary, Tazaki, Koichi, primary, Kojima, Kensuke, primary, Chachad, Dhruv, primary, Zhao, Ran, primary, Heese, Lauren, primary, Ma, Wencai, primary, Ma, Man Chun John, primary, DiNardo, Courtney, primary, Pierce, Sherry, primary, Patel, Keyur P., primary, Tse, Archie, primary, Davis, R. Eric, primary, Rao, Arvind, primary, and Andreeff, Michael, primary

Published
2023
Full Text
View/download PDF

32. Supplemental File 1 from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition

Author

Ishizawa, Jo, primary, Nakamaru, Kenji, primary, Seki, Takahiko, primary, Tazaki, Koichi, primary, Kojima, Kensuke, primary, Chachad, Dhruv, primary, Zhao, Ran, primary, Heese, Lauren, primary, Ma, Wencai, primary, Ma, Man Chun John, primary, DiNardo, Courtney, primary, Pierce, Sherry, primary, Patel, Keyur P., primary, Tse, Archie, primary, Davis, R. Eric, primary, Rao, Arvind, primary, and Andreeff, Michael, primary

Published
2023
Full Text
View/download PDF

33. Supplemental File 2 from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition

Author

Ishizawa, Jo, primary, Nakamaru, Kenji, primary, Seki, Takahiko, primary, Tazaki, Koichi, primary, Kojima, Kensuke, primary, Chachad, Dhruv, primary, Zhao, Ran, primary, Heese, Lauren, primary, Ma, Wencai, primary, Ma, Man Chun John, primary, DiNardo, Courtney, primary, Pierce, Sherry, primary, Patel, Keyur P., primary, Tse, Archie, primary, Davis, R. Eric, primary, Rao, Arvind, primary, and Andreeff, Michael, primary

Published
2023
Full Text
View/download PDF

34. Table S1 from Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas

Author

Pham, Lan V., primary, Huang, Shengjian, primary, Zhang, Hui, primary, Zhang, Jun, primary, Bell, Taylor, primary, Zhou, Shouhao, primary, Pogue, Elizabeth, primary, Ding, Zhiyong, primary, Lam, Laura, primary, Westin, Jason, primary, Davis, R. Eric, primary, Young, Ken H., primary, Medeiros, L. Jeffrey, primary, Ford, Richard J., primary, Nomie, Krystle, primary, Zhang, Leo, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

35. Supplemental Information from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition

Author

Ishizawa, Jo, primary, Nakamaru, Kenji, primary, Seki, Takahiko, primary, Tazaki, Koichi, primary, Kojima, Kensuke, primary, Chachad, Dhruv, primary, Zhao, Ran, primary, Heese, Lauren, primary, Ma, Wencai, primary, Ma, Man Chun John, primary, DiNardo, Courtney, primary, Pierce, Sherry, primary, Patel, Keyur P., primary, Tse, Archie, primary, Davis, R. Eric, primary, Rao, Arvind, primary, and Andreeff, Michael, primary

Published
2023
Full Text
View/download PDF

36. Figure S2 from Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas

Author

Pham, Lan V., primary, Huang, Shengjian, primary, Zhang, Hui, primary, Zhang, Jun, primary, Bell, Taylor, primary, Zhou, Shouhao, primary, Pogue, Elizabeth, primary, Ding, Zhiyong, primary, Lam, Laura, primary, Westin, Jason, primary, Davis, R. Eric, primary, Young, Ken H., primary, Medeiros, L. Jeffrey, primary, Ford, Richard J., primary, Nomie, Krystle, primary, Zhang, Leo, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

37. Data from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition

Author

Ishizawa, Jo, primary, Nakamaru, Kenji, primary, Seki, Takahiko, primary, Tazaki, Koichi, primary, Kojima, Kensuke, primary, Chachad, Dhruv, primary, Zhao, Ran, primary, Heese, Lauren, primary, Ma, Wencai, primary, Ma, Man Chun John, primary, DiNardo, Courtney, primary, Pierce, Sherry, primary, Patel, Keyur P., primary, Tse, Archie, primary, Davis, R. Eric, primary, Rao, Arvind, primary, and Andreeff, Michael, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure Legends from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

Author

Ni, Haiwen, primary, Shirazi, Fazal, primary, Baladandayuthapani, Veerabhadran, primary, Lin, Heather, primary, Kuiatse, Isere, primary, Wang, Hua, primary, Jones, Richard J., primary, Berkova, Zuzana, primary, Hitoshi, Yasumichi, primary, Ansell, Stephen M., primary, Treon, Steven P., primary, Thomas, Sheeba K., primary, Lee, Hans C., primary, Wang, Zhiqiang, primary, Davis, R. Eric, primary, and Orlowski, Robert Z., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure Legends from Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas

Author

Pham, Lan V., primary, Huang, Shengjian, primary, Zhang, Hui, primary, Zhang, Jun, primary, Bell, Taylor, primary, Zhou, Shouhao, primary, Pogue, Elizabeth, primary, Ding, Zhiyong, primary, Lam, Laura, primary, Westin, Jason, primary, Davis, R. Eric, primary, Young, Ken H., primary, Medeiros, L. Jeffrey, primary, Ford, Richard J., primary, Nomie, Krystle, primary, Zhang, Leo, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Tables from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

Author

Ni, Haiwen, primary, Shirazi, Fazal, primary, Baladandayuthapani, Veerabhadran, primary, Lin, Heather, primary, Kuiatse, Isere, primary, Wang, Hua, primary, Jones, Richard J., primary, Berkova, Zuzana, primary, Hitoshi, Yasumichi, primary, Ansell, Stephen M., primary, Treon, Steven P., primary, Thomas, Sheeba K., primary, Lee, Hans C., primary, Wang, Zhiqiang, primary, Davis, R. Eric, primary, and Orlowski, Robert Z., primary

Published
2023
Full Text
View/download PDF

41. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

Author

Bhattacharya, Seemana, primary, Piya, Sujan, additional, Ma, Huaxian, additional, Sharma, Priyanka, additional, Zhang, Qi, additional, Baran, Natalia, additional, Ruvolo, Vivian R., additional, McQueen, Teresa, additional, Davis, R. Eric, additional, Pourebrahim, Rasoul, additional, Konopleva, Marina, additional, Kantarjian, Hagop, additional, Cosford, Nicholas D. P., additional, Andreeff, Michael, additional, and Borthakur, Gautam, additional

Published
2023
Full Text
View/download PDF

42. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

Author

Westin, Jason, primary, Davis, R. Eric, additional, Feng, Lei, additional, Hagemeister, Fredrick, additional, Steiner, Raphael, additional, Lee, Hun Ju, additional, Fayad, Luis, additional, Nastoupil, Loretta, additional, Ahmed, Sairah, additional, Rodriguez, Alma, additional, Fanale, Michelle, additional, Samaniego, Felipe, additional, Iyer, Swaminathan P., additional, Nair, Ranjit, additional, Oki, Yasuhiro, additional, Fowler, Nathan, additional, Wang, Michael, additional, Ma, Man Chun John, additional, Vega, Francisco, additional, McDonnell, Timothy, additional, Pinnix, Chelsea, additional, Griffith, Donna, additional, Lu, Yang, additional, Tewari, Sanjit, additional, Sun, Ryan, additional, Scott, David W., additional, Flowers, Christopher R., additional, Neelapu, Sattva, additional, and Green, Michael R., additional

Published
2023
Full Text
View/download PDF

47. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Author

Fowler, Nathan H, Davis, R Eric, Rawal, Seema, Nastoupil, Loretta, Hagemeister, Fredrick B, McLaughlin, Peter, Kwak, Larry W, Romaguera, Jorge E, Fanale, Michelle A, Fayad, Luis E, Westin, Jason R, Shah, Jatin, Orlowski, Robert Z, Wang, Michael, Turturro, Francesco, Oki, Yasuhiro, Claret, Linda C, Feng, Lei, Baladandayuthapani, Veerabhadran, Muzzafar, Tariq, Tsai, Kenneth Y, Samaniego, Felipe, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

49. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Author

Westin, Jason R, Chu, Fuliang, Zhang, Min, Fayad, Luis E, Kwak, Larry W, Fowler, Nathan, Romaguera, Jorge, Hagemeister, Fredrick, Fanale, Michelle, Samaniego, Felipe, Feng, Lei, Baladandayuthapani, Veerabhadran, Wang, Zhiqiang, Ma, Wencai, Gao, Yanli, Wallace, Michael, Vence, Luis M, Radvanyi, Laszlo, Muzzafar, Tariq, Rotem-Yehudar, Rinat, Davis, R Eric, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results